By Dr. Brandon Bright, DAOM, LAc · Doctor of Acupuncture & Oriental Medicine · Functional Medicine University-certified · Tustin, CA · Last reviewed: September 6, 2026
On September 3, Oura filed its S-1 — the formal registration to go public on Nasdaq under the ticker OURA. IPO filings are usually investor reading, but this one is worth ten minutes of any health-conscious patient’s time, because an S-1 is the one document where a company is legally required to tell you the unvarnished truth about its business — including the parts marketing never mentions. Oura’s filing delivers on both fronts: numbers that prove how enormous the sleep-data business has become, and a risk-factors section that formally discloses the sleep-accuracy lawsuit filed against the company in August. I read the filing so you don’t have to. Here’s what it says, in patient terms — about the company, about the wearable category, and about what your nightly data is actually worth.
The 55-second answer
The filing shows a genuinely strong business: $1.21 billion in revenue for the nine months ended June 30 (up 74%), roughly $60.8M in operating profit, and 5 million paid members — double a year ago — with 85% member retention and an 89% gross margin on membership revenue. Translation: your $6/month subscription, multiplied by millions, is one of the best businesses in consumer health, and the market may value it above $16 billion. The same filing formally discloses, in its risk factors, the August class action alleging the company “falsely advertise[s] the accuracy of our sleep-tracking technology” — an allegation, unresolved, which Oura disputes, but now permanently attached to the company in a federal document every investor must read. The patient takeaway isn’t “sell your ring.” It’s that the filing confirms both halves of what we’ve been saying: sleep data collection is a phenomenal business, and the accuracy of that data is a live, contested question — which makes how you use the data (trends, not absolutes; interpretation, not scores) matter more than ever.
The numbers, and what they mean for a member
- Revenue $1.21B in nine months, +74% year over year. The ring is now mainstream, not a biohacker niche — and category scale brings scrutiny (regulators, plaintiffs, and journalists all read S-1s).
- 5 million paid members, up from 2.5M in a year. The doubling matters for you in one specific way: the value of the company is substantially the value of the recurring membership — which means the product’s job, structurally, is to keep you engaged with your data daily. Worth remembering when the app nudges you to check your readiness score every morning. Engagement design isn’t sinister; it’s just not the same thing as clinical necessity.
- Membership revenue +121%, at 89% gross margin, with 85% retention. The subscription — the data-interpretation layer — is the profit engine, not the hardware. The category-wide lesson (Oura, WHOOP, Hims’s free scale alike): hardware is bait; your data relationship is the business.
- Operationally profitable (~$60.8M net income). Notable because most digital-health companies aren’t. If you see headlines about a “$924M loss,” that figure is an accounting artifact of the pre-IPO share structure (a one-time deemed dividend to preferred shareholders), not the operating business. Both numbers are in the filing; only one describes the actual company.
The risk factors: where marketing meets oath
The S-1’s risk-factors section is my favorite genre of corporate literature, because it’s the anti-marketing: the company’s lawyers listing everything that could go wrong, under liability if they omit something material. Three disclosures matter for patients:
1. The accuracy lawsuit, verbatim. The filing states that “in August 2026, a class action was filed against us alleging that we falsely advertise the accuracy of our sleep-tracking technology,” adding that litigation is uncertain and that similar claims may follow. To be scrupulously fair: this is a disclosure of an allegation, not an admission — companies must disclose material suits regardless of merit, and Oura disputes the claims. But the placement is meaningful: sleep-staging accuracy is now a formally acknowledged business risk. (For what the accuracy science actually shows — good trend data, weak minute-level staging, category-wide — the full sleep-tracker accuracy guide is here.)
2. The filing invites accuracy scrutiny category-wide. When the largest wearable IPO of the year carries an accuracy suit in its risk factors, every competitor’s marketing team takes notes. Watch for a quiet industry-wide softening of sleep-staging claims — “estimates” and “insights” replacing “measures.” That would be a win for honest labeling that no regulator had to force.
3. Litigation is a cost of scale, not necessarily a scandal. The filing also discloses unrelated suits (an equity-compensation claim by a well-known health influencer, and claims from a former CEO). Big companies collect lawsuits. The reason the accuracy suit is the one that matters to you is that it’s the only one about the product’s core promise.
What this means for how you use your ring
Nothing in the S-1 changes the practical guidance — it reinforces it with the company’s own numbers:
- The subscription’s value to you is trends. The 85% of members who stay clearly get something — and the something that’s scientifically defensible is longitudinal trend data: sleep drifting worse over weeks, HRV baseline shifting, resting heart rate creeping. That’s real signal worth $6/month to many people.
- The nightly absolutes are estimates — now formally contested ones. Deep-sleep minutes and readiness scores are inferences. Use them loosely; never let a score overrule how you feel.
- Your data’s business value ≠ its clinical value. Five million subscriptions prove the data is worth billions in aggregate. Its value to your health is only realized when someone competent interprets it in your context — which is the layer no wearable sells. A falling HRV trend means different things in an overtrained athlete, a perimenopausal patient (where wearables misread the picture routinely), and someone with untreated apnea. At the Tustin practice, patients’ wearable exports are a standard input to the clinical picture — the device is a good witness and a poor judge. First visit $199 in person, $150 virtual.
- Check your data settings before the IPO, not after. Public-company incentives sharpen quarterly. Your ring’s data-sharing preferences, research opt-ins, and export options are worth five minutes now — the same hygiene that applies to every wellness app outside HIPAA’s fence.
Frequently asked questions
Should I stop using my Oura ring because of the lawsuit?
No — an unresolved allegation about marketing claims isn’t a reason to discard a useful trend-tracking tool. It’s a reason to use the tool for what it demonstrably does (trends) rather than what’s contested (precise staging).
Will the IPO change my subscription price?
The filing doesn’t say, and no change has been announced. Public-company margin pressure makes subscription economics a thing to watch over time — as with every subscription you own.
Is my Oura data protected if the company goes public?
Going public doesn’t change the legal status of your data — consumer wellness data remains outside HIPAA either way, governed by the privacy policy. It does add public-market pressure to monetize; review your sharing settings and keep your own exports.
Is Oura profitable — I saw a headline about huge losses?
Operationally profitable (~$60.8M net income on the nine months). The near-billion-dollar “loss” figure is a one-time accounting charge tied to pre-IPO preferred shares — real in accounting terms, irrelevant to whether the business makes money.
What should I actually watch next?
The pricing terms (expected around late September), whether sleep-staging marketing language softens across the category, and — if you care about the accuracy question — the lawsuit’s docket, which will move far slower than the IPO.
Dr. Brandon Bright is a Doctor of Acupuncture and Oriental Medicine (DAOM), Licensed Acupuncturist in California, and Functional Medicine University-certified. He runs a multi-modality holistic medicine practice at 13732 Newport Ave STE 2, Tustin, CA 92780. Phone: 714-206-7883. He has no financial relationship with Oura or any wearable maker, and no position in any security mentioned. He is not a medical doctor and this is not investment advice; S-1 figures are from the public SEC filing, and the lawsuit described is an unresolved allegation, not a finding. Educational content only.